Absci reports Q4 net loss $29.6M, advances ABS-201 trial, appoints new CMO

Absci Corp

Dosed first three cohorts in SAD portion of Phase 1/2a HEADLINE trial for ABS-201; well-tolerated with favorable emerging safety.
Net loss Q4 2025 $29.6M vs $29.0M prior year; full year net loss $115.2M vs $103.1M.
Cash, equivalents, and marketable securities $144.3M as of Dec 31, 2025; sufficient to fund operations into first half 2028.
Appointed Ransi Somaratne, M.D. (former Vertex SVP) as Chief Medical Officer to lead clinical strategy.
Interim proof-of-concept data for ABS-201 expected H2 2026; Phase 2 endometriosis trial initiation planned Q4 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Absci Corp reported the quarter and full year ended December 31, 2025 results: revenue $0.7 million for the three months ended December 31, 2025 compared to $0.7 million for the three months ended December 3.

Period: the quarter and full year ended December 31, 2025
Revenue: $0.7 million for the three months ended December 31, 2025 compared to $0.7 million for the three months ended December 3
Result: reported results

Exact text from the filing

On March 24, 2026, Absci Corporation (the “Company”) announced its financial results for the fourth quarter ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

Absci Corp filing history →

Source: SEC EDGAR

accession 0001672688-26-000066

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.